


CORRECTION

Correction: Interferon β -1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial

The *PLOS ONE* Staff

There is an error in affiliation 3 for author Darren P. Baker. Affiliation 3 should be: Sanofi Genzyme, Cambridge, Massachusetts, United States of America.

There is an error in the caption for [Fig 2](#). Please see the complete, correct [Fig 2](#) caption here. The publisher apologizes for these errors.



OPEN ACCESS

Citation: The *PLOS ONE* Staff (2017) Correction: Interferon β -1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. *PLoS ONE* 12(4): e0175930. <https://doi.org/10.1371/journal.pone.0175930>

Published: April 12, 2017

Copyright: © 2017 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 2. IFN β-1a treatment effect on survival of patients with EVD. Survival curves for patients with EVD receiving supportive care only (n = 21) (solid line) or supportive care plus IFN β-1a treatment (n = 9) (dashed line). Survival was calculated from the date of consent for those receiving IFN β-1a treatment and date of admission for those in the control cohort, to the date of death. Survival plots were based on Kaplan-Meier estimates and the plots were compared using the log rank test (p = 0.026).

<https://doi.org/10.1371/journal.pone.0175930.g001>

Reference

1. Konde MK, Baker DP, Traore FA, Sow MS, Camara A, Barry AA, et al. (2017) Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE 12(2): e0169255. doi:[10.1371/journal.pone.0169255](https://doi.org/10.1371/journal.pone.0169255) PMID: [28225767](https://pubmed.ncbi.nlm.nih.gov/28225767/)